Loargys (pegzilarginase-nbln) is indicated for the treatment of Arginase 1 Deficiency (ARG1-D), also known as hyperargininemia, in adult and pediatric patients 2 years of age and older, a rare urea cycle disorder characterized by elevated plasma arginine levels and progressive neurological impairment.

Loargys functions as an enzyme replacement therapy, reducing toxic arginine accumulation and helping to manage the metabolic and neurological complications associated with the disease. Meanwhile, Yuviwel (navepegritide) is approved under the FDA’s accelerated approval pathway to increase linear growth in pediatric patients aged 2 years and older with achondroplasia who have open epiphyses, acting as a C-type natriuretic peptide analog to address impaired endochondral bone growth. Both therapies represent high-value rare disease and pediatric indications, where regulatory exclusivity periods, orphan drug status, and market entry barriers play a pivotal role in lifecycle management, biosimilar considerations, and long-term competitive strategy.